文献速递神经肌肉病

年轻未使用糖皮质激素的杜氏肌营养不良男孩的临床与遗传特征

Clinical and Genetic Characteristics in Young, Glucocorticoid-Naive Boys With Duchenne Muscular Dystrophy.
PubMed 文献 · Neurology · 2022-01-24

本研究基于FOR-DMD试验的筛选与基线数据,描述了196例4至<8岁未使用糖皮质激素的杜氏肌营养不良男孩的临床与遗传特征。主要突变类型为框外缺失(67.4%,130/193),其中68.5%可行外显子跳跃治疗。仅外显子8可跳跃缺失男孩的10米步行/跑步时间表现优于不可跳跃缺失男孩(p=0.02)。

要点

  • 首次父母担忧的平均年龄为29.8±18.7个月,基因诊断平均年龄为53.9±21.9个月,平均诊断延迟25.9±18.2个月。
  • 因孤立性高肌酸激酶血症偶然发现而诊断的男孩(n=19)平均诊断延迟为6.4±7.4个月。
  • 无论年龄组,身高中位数百分位均低于第25百分位。

核心结论

  • 本研究描述了年轻未使用糖皮质激素的杜氏营养不良男孩样本的临床与遗传特征,发现低阈值肌酸激酶检测可导致更早诊断,运动和语言发育延迟是常见首发症状,低治疗前身高对生长和成年身高的影响需进一步研究。

研究设计与样本

  • 研究基于国际、多中心、随机、双盲临床试验FOR-DMD的筛选和基线数据,该试验比较3种糖皮质激素方案在4至<8岁、基因确诊、未使用糖皮质激素的杜氏营养不良男孩中的效果,共招募196例男孩。

主要发现

  • 随机分组时平均±标准差年龄为5.8±1.0岁;主要突变类型为框外缺失(67.4%,130/193),其中68.5%(89/130)可行外显子跳跃治疗;最常见突变为可行外显子51跳跃的缺失(13.0%,25/193);终止密码子突变占10.4%(20/193)。
  • 首次父母担忧的平均年龄为29.8±18.7个月,基因诊断平均年龄为53.9±21.9个月,平均诊断延迟为25.9±18.2个月;因孤立性高肌酸激酶血症偶然发现而诊断的男孩(n=19)平均诊断延迟为6.4±7.4个月。
  • 独立行走和说句子的平均年龄分别为17.1±4.2个月和29.0±10.7个月;无论年龄组,身高中位数百分位均低于第25百分位。
  • 除外的基因型-表型关联:外显子8可跳跃缺失男孩在10米步行/跑步时间上表现优于不可跳跃缺失男孩(p=0.02)。

临床怎么用

  • 作者认为低阈值肌酸激酶检测可导致更早诊断,运动和语言发育延迟是常见首发症状,这些发现可能促进杜氏营养不良的更早识别并为未来临床试验设计提供信息。

局限性

  • 低治疗前身高对生长和成年身高的影响需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Duchenne muscular dystrophy (DMD) is a pediatric neuromuscular disorder caused by mutations in the dystrophin gene. Genotype-phenotype associations have been examined in glucocorticoid-treated boys, but there are few data on the young glucocorticoid-naive DMD population. A sample of young glucocorticoid-naive DMD boys is described, and genotype-phenotype associations are investigated. METHODS: Screening and baseline data were collected for all the participants in the Finding the Optimum Corticosteroid Regime for Duchenne Muscular Dystrophy (FOR-DMD) study, an international, multicenter, randomized, double-blind, clinical trial comparing 3 glucocorticoid regimens in glucocorticoid-naive, genetically confirmed boys with DMD between 4 and <8 years of age. RESULTS: One hundred ninety-six boys were recruited. The mean ± SD age at randomization was 5.8 ± 1.0 years. The predominant mutation type was out-of-frame deletions (67.4%, 130 of 193), of which 68.5% (89 of 130) were amenable to exon skipping. The most frequent mutations were deletions amenable to exon 51 skipping (13.0%, 25 of 193). Stop codon mutations accounted for 10.4% (20 of 193). The mean age at first parental concerns was 29.8 ± 18.7 months; the mean age at genetic diagnosis was 53.9 ± 21.9 months; and the mean diagnostic delay was 25.9 ± 18.2 months. The mean diagnostic delay for boys diagnosed after an incidental finding of isolated hyperCKemia (n = 19) was 6.4 ± 7.4 months. The mean ages at independent walking and talking in sentences were 17.1 ± 4.2 and 29.0 ± 10.7 months, respectively. Median height percentiles were below the 25th percentile regardless of age group. No genotype-phenotype associations were identified expect for boys with exon 8 skippable deletions, who had better performance on time to walk/run 10 m (p = 0.02) compared to boys with deletions not amenable to skipping. DISCUSSION: This study describes clinical and genetic characteristics of a sample of young glucocorticoid-naive boys with DMD. A low threshold for creatine kinase testing can lead to an earlier diagnosis. Motor and speech delays were common presenting symptoms. The effects of low pretreatment height on growth and adult height require further study. These findings may promote earlier recognition of DMD and inform study design for future clinical trials. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT01603407.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schiava M, Amos R, VanRuiten H, et al. Clinical and Genetic Characteristics in Young, Glucocorticoid-Naive Boys With Duchenne Muscular Dystrophy. Neurology. 2022. PMID: 34857536. doi:10.1212/WNL.0000000000013122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。